Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | M6PR | P20645 | 2/20 | 0.34 |
| ▸ | FGF1 | P05230 | 2/20 | 0.33 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 2/20 | 0.32 |
| ▸ | AMY2A | P04746 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18120604 | 1.00 | M6PR (0.34) | M6PRFGF1SYNJ2G6PDAMY2A | |
| SCHEMBL12755227 | 1.00 | M6PR (0.34) | M6PRFGF1SYNJ2G6PDAMY2A | |
| SCHEMBL15445588 | 1.00 | M6PR (0.34) | M6PRFGF1SYNJ2G6PDAMY2A | |
| SCHEMBL26361826 | 1.00 | M6PR (0.34) | M6PRFGF1SYNJ2G6PDAMY2A | |
| SCHEMBL25788678 | 1.00 | M6PR (0.34) | M6PRFGF1SYNJ2G6PDAMY2A | |
| SCHEMBL12304925 | 1.00 | M6PR (0.34) | M6PRFGF1SYNJ2G6PDAMY2A | |
| SCHEMBL12895439 | 1.00 | M6PR (0.34) | M6PRFGF1SYNJ2G6PDAMY2A | |
| SCHEMBL25679798 | 1.00 | M6PR (0.34) | M6PRFGF1SYNJ2G6PDAMY2A | |
| SCHEMBL25788664 | 1.00 | M6PR (0.34) | M6PRFGF1SYNJ2G6PDAMY2A | |
| SCHEMBL12755228 | 0.90 | F10 (0.38) | FGF1F10LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250170-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2016-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250170-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, DDO, DAO | M6PR 569/4885FGF1 2014/4885SYNJ2 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.